Mandate

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

November 06, 2019 Capital Markets and Public M&A

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

The subscription price was determined to SEK 186.50 per share through an accelerated book building process. The share issue was directed to approximately 130 Swedish and international institutional investors. The purpose of the share issue is increase the financial flexibility for additional acquisitions and further strengthen the company’s competitive position in the international hotel property market.

Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025